Compare
Amneal Pharmaceuticals vs Johnson & Johnson (AMRX vs JNJ)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Amneal Pharmaceuticals (AMRX) returned +72.3% and Johnson & Johnson (JNJ) +48.5%; so far this year the figures are +59.8% and +33.5%.
Johnson & Johnson is the larger company by market value, about 103.4 times the size of Amneal Pharmaceuticals.
On trailing earnings, AMRX trades at 41.1 times and JNJ at 41.9 times.
Revenue grew +9.3% at AMRX and +7.8% at JNJ over the last year.
AMRX pays no dividend. JNJ yields 1.91%.
Data as of the latest close. Not investment advice.
Relative performance
| AMRX | JNJ | |
|---|---|---|
| Price | $20.14 | $276.22 |
| 1-day | +3.55% | +1.43% |
| YTD | +59.84% | +33.47% |
| 1 year | +72.28% | +48.51% |
| 3 years | +417.74% | +85.77% |
| Market cap | $6.4B | $665.0B |
| P/E | 41.1 | 41.9 |
| P/S | 2.06 | 6.69 |
| P/B | 194.76 | 8.16 |
| Revenue growth | +9.30% | +7.80% |
| EPS growth | +4800.00% | -36.40% |
| Gross margin % | 39.3 | 67.6 |
| Net margin % | 5.0 | 16.2 |
| ROE % | 476.5 | 19.7 |
| Debt / equity | 77.83 | 0.55 |
| FCF yield % | 2.0 | 3.1 |
| Dividend yield % | — | 1.91 |
| Beta | 0.62 | -0.09 |
| RSI (14) | 50.8 | 59.4 |
| Technical rating |